文献速递淋巴瘤

丙戊酸联合利妥昔单抗与CHOP作为弥漫性大B细胞淋巴瘤一线治疗(VALFRID)

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
PubMed 文献 · Blood Adv · 2018-01-01

本研究为1期剂量递增及扩展研究,旨在确定丙戊酸联合R-CHOP治疗弥漫性大B细胞淋巴瘤的最大耐受剂量。丙戊酸最大耐受剂量为每日60 mg/kg,更高剂量导致听觉不良事件。2年无进展生存率为84.7%(95%CI 73.2%-98%),2年总生存率为96.8%(n=31;95%CI 90.8%-100%)。与瑞典淋巴瘤登记处两个风险因素匹配的R-CHOP治疗患者队列(A组n=330,B组n=165)相比,加用丙戊酸对总生存有统计学显著获益(P=.034和0.028)。

要点

  • 丙戊酸联合R-CHOP的最大耐受剂量为每日60 mg/kg,推荐2期剂量为每日60 mg/kg联合泼尼松。
  • 2年无进展生存率84.7%(95%CI 73.2%-98%),2年总生存率96.8%(n=31;95%CI 90.8%-100%)。
  • 与匹配队列相比,加用丙戊酸对总生存有统计学显著获益(P=.034和0.028),听觉不良事件需密切监测。

核心结论

  • 丙戊酸联合R-CHOP是弥漫性大B细胞淋巴瘤一线治疗的可行策略。
  • 靶向组蛋白去乙酰化的药物与标准R-CHOP联合可能带来获益且可耐受。
  • 听觉不良事件出乎意料,需要密切监测。

研究设计与样本

  • 1期剂量递增研究,随后使用已确定的最大耐受剂量进行剂量扩展研究。
  • 研究对象为弥漫性大B细胞淋巴瘤患者。
  • 1期试验在www.clinicaltrials.gov注册,注册号为#NCT01622439。

主要发现

  • 丙戊酸联合R-CHOP的最大耐受剂量确定为每日60 mg/kg,更高剂量导致听觉不良事件。
  • 2年无进展生存率为84.7%(95%CI 73.2%-98%)。
  • 2年总生存率为96.8%(n=31;95%CI 90.8%-100%)。
  • 与瑞典淋巴瘤登记处两个风险因素匹配的R-CHOP治疗患者队列(A组n=330,B组n=165)相比,加用丙戊酸对总生存有统计学显著获益(P=.034和0.028)。

关键数值与推荐

  • 丙戊酸联合R-CHOP的最大耐受剂量为每日60 mg/kg。
  • 提出的2期剂量为每日60 mg/kg联合泼尼松。
  • 2年无进展生存率84.7%(95%CI 73.2%-98%)。
  • 2年总生存率96.8%(n=31;95%CI 90.8%-100%)。
  • 与匹配队列比较的总生存P值分别为P=.034和0.028。

临床怎么用

  • 作者认为,丙戊酸联合R-CHOP是弥漫性大B细胞淋巴瘤一线治疗的可行策略。
  • 作者提出2期剂量为每日60 mg/kg联合泼尼松。
  • 作者指出听觉不良事件出乎意料,需要密切监测。
  • 作者认为靶向组蛋白去乙酰化的药物与标准R-CHOP联合可能带来获益且可耐受。

局限性

  • 听觉不良事件出乎意料,需要密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aims of the present study were to establish the maximally tolerated dose (MTD) of the histone deacetylase inhibitor valproate together with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL). A phase 1 dose escalation study of valproate together with R-CHOP followed by a dose expansion study using the established MTD of valproate was performed. MTD of valproate together with R-CHOP was established at 60 mg/kg per day, as higher doses resulted in auditory adverse events (AEs). In the study population, 2-year progression-free survival was 84.7% (95% confidence interval [CI], 73.2%-98%). The 2-year overall survival (OS) was 96.8% (n = 31; 95% CI, 90.8%-100%). These data were compared with 2 risk-factor matched populations of R-CHOP-treated patients from the Swedish Lymphoma Registry (cohort A, n = 330 and B, n = 165). As compared with the matched cohorts, we observed a statistically significant (P = .034 and 0.028, respectively) beneficial effect of the addition of valproate to R-CHOP on the OS in the studied population. In conclusion, addition of valproate to R-CHOP is a feasible strategy in first-line treatment of DLBCL. The proposed phase 2 dose is 60 mg/kg per day together with prednisone. Auditory AEs were unexpected and warrant close monitoring. Our findings suggest that drugs that target histone deacetylation may add benefit and are tolerable when combined with standard R-CHOP in DLBCL. The phase 1 trial was registered at www.clinicaltrials.gov as #NCT01622439.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Drott K, Hagberg H, Papworth K, et al. Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). Blood Adv. 2018. PMID: 29903707. doi:10.1182/bloodadvances.2018019240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。